Polaris Group announced the approval of phase 2 clinical protocol treating GBM with ADI-PEG 20, Phase 2 trial is a global, multi-center, randomized, double-blind, placebo controlled study to enroll 100 patients. The primary endpoint is Overall Survival and secondary endpoints are PFS, DOR and Response Rate will be examined based on investigators and assessments. Current development stage: File application/approved/disapproved/Each of clinical trials (include interim analysis): approved by MFDS for clinical 2 trial.

Accumulated investment expenditure incurred: No disclosure due to confidentiality.